Mifobate
Product Specifications
UNSPSC Description
Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects[1].
Target Antigen
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/mifobate.html
Purity
99.10
Solubility
H2O : 35.87 mg/mL (ultrasonic;warming)|DMSO : 100 mg/mL (ultrasonic)
Smiles
O=P(OC)(OC)OC(C1=CC=C(Cl)C=C1)P(OC)(OC)=O
Molecular Weight
358.65
References & Citations
[1]Rieusset J, et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesityand antidiabetic activity. Mol Endocrinol. 2002 Nov;16(11):2628-44.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-100277/Mifobate-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-100277/Mifobate-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
76541-72-5
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
